Cara Therapeutics (CARA) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cara Therapeutics Reports Second Quarter 2022 Financial Results
August 8, 2022 4:01 PM EDTNet revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin)
KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022
Conference call today at 4:30 p.m. ET
STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical... More
